A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.

Summary

This is a randomized, placebo-controlled, Phase 2b study to evaluate the efficacy, safety, and tolerability of CBL-514 injection compared with CBL-A1 and CBL-A2 for reducing subcutaneous fat.

Timeline

Start

2023-11-10

Primary completion

2024-10-18

Completion

2024-10-18

Outcome

Met primary endpoint

release “CBL-0205 Phase 2b成功達成主要療效及多項次要療效指標” caliwaybiopharma.com ↗

Drugs

Indications